NasdaqGS:APLSBiotechs
Does Apellis Pharmaceuticals' (APLS) New Board Member Reveal a Deeper R&D Commercialization Strategy Shift?
Apellis Pharmaceuticals recently added Mikael Dolsten, M.D., Ph.D., former chief scientific officer of Pfizer, to its board of directors, bringing decades of high-level research and development leadership across major global drug makers.
This appointment, alongside growing analyst interest in Apellis’s key products Empaveli and Syfovre, underscores how external experts view the company’s pipeline and commercial portfolio as increasingly relevant in rare kidney disease and eye care...